ESALY News and Press, Eisai Co. Ltd. ADR From 10/05/22

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Reportedly, Biogen  (NASDAQ: BIIB ) and Japanese pharmaceutical company Eisai  (OTCMKTS: ESALY ) achieved positive test results for their Alzheimer’s disease treatment. As you might expect, BIIB...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cassava Sciences (NASDAQ: SAVA ) stock took off once again during September. Rumors about the Securities and Exchange Commission (or SEC) clearing its investigation of the scandal-tarnished biotech firm resulted in a bi...

Summary Non-APOE4 carriers do not benefit from treatment with lecanemab. Lecanemab reduces the rate of progression of APOE4 carriers closer to that of non-carriers in mild Alzheimer's disease. While rare, brain swelling and brain bleeds may occur in APOE4 carriers on lecanemab...

Eisai Completes Construction of Its New Injection/Research Building at Kawashima Industrial Park in Japan TOKYO, Oct 4, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced that, as part of the strategic investment towards the realization of its medium-term business plan "EWAY Fu...

Summary Eisai and Biogen get another chance. Still not a cure, but a big step forward even though it's still just a glimmer of hope for Alzheimer’s sufferers. The big news is that lecanemab produced a measurable effect for slowing early Alzheimer’s. The question ...

Summary Biogen and Eisai announce positive clinical results for lecanemab, a novel treatment for Alzheimer’s disease. Lecanemab continues the collaboration between the companies, after the controversial approval of Aduhelm last year. Both Biogen and Eisai are up over 35...

Tens of millions of Alzheimer's disease patients were given a rare dose of good news recently when Biogen (NASDAQ: BIIB) released some encouraging clinical trial results for its new Alzheimer's disease treatment candidate. The data from a big pivotal trial of that experimental treat...

Biogen ( NASDAQ: BIIB ) and Eisai ( OTCPK:ESALY ) weren't the only drug companies developing Alzheimer's treatments that finished Wednesday significantly higher. The duo closed up, respectively, 40% and ~58% higher following Tuesday's after the market close release o...

Summary The big news last night was the announcement of a positive readout in Eisai and Biogen's trial of lecanemab, another attempt at an anti-amyloid antibody for Alzheimer's therapy. As the world knows, the anti-amyloid clinical landscape for Alzheimer's is absolutely littered ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Amid a notable positive session for the major equity indices, Biogen (NASDAQ: BIIB ) really got the party started with a massive 37% boost in the early afternoon session on Wednesday. Biogen disclosed very encouraging r...